1. Home
  2. |Insights
  3. |"Improper Revival" Not A Cognizable Defense In An Action Involving The Validity Or Infringement Of A Patent

"Improper Revival" Not A Cognizable Defense In An Action Involving The Validity Or Infringement Of A Patent

Client Alert | less than 1 min read | 09.24.08

In Aristocrat Technologies Australia PTY Ltd. v. International Game Tech. (No. 2008-1016; Sept. 22, 2008), the Federal Circuit reverses a district court's grant of summary judgment that U.S. Patent No. 7,056,215 ("the '215 patent"), and the continuation patent that followed it, are invalid on the grounds that the U.S. Patent and Trademark Office "improperly revived" the '215 patent after it was abandoned during prosecution. The Federal Circuit holds that "improper revival" is not a cognizable defense in an action involving the validity or infringement of a patent, reasoning that the proper revival of an abandoned application is not a defense recognized by the patent statute nor is it a ground specified in the patent statute as a condition for patentability.

Contacts

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...